Savara shuts down an­oth­er cys­tic fi­bro­sis pro­gram af­ter a PhI­II flop, as it pre­pares to axe staff and re-cen­ter around aPAP

2020 hasn’t been a good year for Savara Phar­ma­ceu­ti­cals, and the hits kept com­ing as an­oth­er tri­al in cys­tic fi­bro­sis flopped Fri­day.

The Austin, TX-based biotech re­port­ed that a Phase III study eval­u­at­ing its in­haled AeroVanc pow­der missed the pri­ma­ry end­point in pa­tients with CF who have a MR­SA lung in­fec­tion. It’s the sec­ond tri­al in four months Savara has dis­con­tin­ued, as a Phase II for its lead pro­gram mol­gradex was shut down fol­low­ing the suc­cess of a CF drug from Ver­tex and the Covid-19 pan­dem­ic com­pli­cat­ing tri­al re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER